drugset / Trial / NCT00983424

Cyclosporine A in Combination With Nab-Paclitaxel in Patients With Metastatic Breast Cancer

NCT00983424

Phase 1 Completed 14 enrolled Northwestern University Avon Foundation · collab
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this research study is to evaluate the safety of therapy with nab-paclitaxel and CsA and if the addition of Cyclosporine A (CsA) to nab-paclitaxel helps stop cancer cells as well as or better than nab-paclitaxel alone.

Timeline

Start
2010-02
Primary completion
2013-05
Completion
2013-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Cyclosporine Peptide Oral
Subject Paclitaxel Small molecule 100 mg/m2 Intravenous

Indications